Exclusive: US FDA finds new manufacturing lapses at Eli Lilly plant

19 Jan 2024
www.reuters.com
Drug Approval
Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo Acquire Licensing Rights, opens new tab
Reporting by Marisa Taylor in Washington and Maggie Fick in London; Additional reporting by Patrick Wingrove in New York; Editing by Michele Gershberg, Bill Berkrot and Daniel Wallis
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Exclusive: US FDA finds new manufacturing lapses at Eli Lilly plant
Preview
Source: Reuters
Exclusive: US FDA finds new manufacturing lapses at Eli Lilly plant
Preview
Source: Reuters
Exclusive: US FDA finds new manufacturing lapses at Eli Lilly plant
Preview
Source: Reuters
Exclusive: US FDA finds new manufacturing lapses at Eli Lilly plant
Preview
Source: Reuters
Exclusive: US FDA finds new manufacturing lapses at Eli Lilly plant
Preview
Source: Reuters
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.